The incidence of blood clots in persons who received AstraZeneca and Pfizer Covid vaccinations were ‘similar.’ – research
During the pandemic, ASTRAZENECA received a lot of backlash since the vaccination was connected to a rare blood clot problem. Despite the media interest, a new study indicated that those who received the Pfizer vaccine had identical rates of blood clotting.
Since its introduction into different communities, the AstraZeneca coronavirus vaccine has been involved in controversy. The uproar erupted after reports of a rare but deadly illness involving blood clots and unusual bleeding following an AstraZeneca immunization. Fears regarding the vaccination were heightened by the EU, which was led by French President Emmanuel Macron. The vaccination was branded “quasi-ineffective” un over-65s by the French President in January. However, the risk of acquiring a blood clot is extremely low, and a new study reveals that you are no more likely to get one after getting the AstraZeneca vaccine than you are after getting the Pfizer vaccine.
According to experts, patients who received the AstraZeneca COVID-19 vaccine experienced blood clotting disorders at a “similar” incidence to those who received the Pfizer/BioNTech vaccine after getting the AstraZeneca COVID-19 vaccine.
A group of researchers from Spain, the United Kingdom, and the Netherlands reviewed data from almost 1.3 million people in Catalonia who had had COVID injections, seeking for evidence of blood clotting disorders that arose after the shots.
“Similar safety profiles were seen for both vaccines in this study of 1,372,213 patients immunized against SARS-CoV-2,” the researchers stated in their pre-print publication, which has not been peer-reviewed.
The study also confirmed that not getting immunized has significantly larger dangers.
They discovered that persons who were infected with COVID-19 had a far higher rate of blood clots than those who had received the AstraZeneca or Pfizer/BioNTech vaccinations.
The preliminary findings follow a turbulent era for AstraZeneca’s vaccine.
Fearing that the vaccination would constitute a public health concern, many governments have stockpiled vaccines in refrigerators.
The fear has been heightened in part as a result of examinations into the vaccine’s link to blood clots by leading health organizations.
The European Medicines Agency (EMA) reported in April that the vaccination was linked to “extremely uncommon incidences of atypical blood clots with low blood platelets.”
Many governments throughout the world have halted or discontinued their campaigns as a result of the finding.
The Joint Committee on Vaccination and Immunization (JCVI) in the United Kingdom updated its recommendations. “Brinkwire News in Condensed Form.”